Skip to main content
Access Resources

MJFF Publications

641 - 650 of 7370 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • OPEN
    Title: Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy Controls
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903096.36040.1d
    Citation Count: 0
  • OPEN
    Title: Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-022-34732-5
    Citation Count: 16
  • OPEN
    Title: Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 Sequences
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903160.72715.2d
    Citation Count: 1
  • OPEN
    Title: Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903320.23411.f9
    Citation Count: 0
  • OPEN
    Title: Substitution of PINK1 Gly411 modulates substrate receptivity and turnover
    Journal Name: Autophagy
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1080/15548627.2022.2151294
    Citation Count: 4
  • OPEN
    Title: The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903316.50895.83
    Citation Count: 1
  • RESTRICTED
    Title: Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-Encephalitis
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903424.19914.85
    Best OA location URL:
    Citation Count: 0
  • OPEN
    Title: Synapsin III Regulates Dopaminergic Neuron Development in Vertebrates
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells11233902
    Citation Count: 1
  • RESTRICTED
    Title: Agglomerative and divisive hierarchical Bayesian clustering
    Journal Name: Computational Statistics & Data Analysis
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.csda.2022.107566
    Best OA location URL:
    Citation Count: 3
  • OPEN
    Title: Anionic lipid vesicles have differential effects on the aggregation of early onset-associated α-synuclein missense mutants
    Journal Name: Journal of Biological Chemistry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.jbc.2022.102565
    Citation Count: 1
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.